The precise role of TGF-b in colorectal carcinogenesis is not clear. The purpose of this study was to determine the phenotypic alterations caused by chronic exposure to TGF-b in non-transformed intestinal epithelial (RIE-1) cells. Growth of RIE-1 cells was inhibited by 475% following TGF-b1 treatment for 7 days, after which the cells resumed a normal growth despite the presence of TGF-b1. These`TGF-b-resistant' cells (RIE-Tr) were continuously exposed to TGF-b for 450 days. Unlike the parental RIE cells, RIE-Tr cells lost contact inhibition, formed foci in culture, grew in soft agarose. RIE-Tr cells demonstrated TGF-b-dependent invasive potential in an in vitro assay and were resistant to Matrigel and Na-butyrate-induced apoptosis. The RIETr cells were also tumorigenic in nude mice. The transformed phenotype of RIE-Tr cells was associated with a 95% decrease in the level of the type II TGF-b receptor (TbRII) protein, a 40-fold increase in cyclooxygenase-2 (COX-2) protein, and 5.9-fold increase in the production of prostacyclin. Most RIE-Tr subclones that expressed low levels of TbRII and high levels of COX-2 were tumorigenic. Those subclones that express abundant TbRII and low levels of COX-2 were not tumorigenic in nude mice. A selective COX-2 inhibitor inhibited RIE-Tr cell growth in culture and tumor growth in nude mice. The reduced expression of TbRII, increased expression of COX-2, and the ability to form colonies in Matrigel were all reversible upon withdrawal of exogenous TGFb1 for the RIE-Tr cells.
Introduction
TGF-bs are known to regulate many biological processes including cellular proliferation, cell migration, dierentiation, and extracellular matrix deposition. TGF-b is a potent negative growth-regulator for epithelial cells and TGF-b receptor signaling appears to serve an important tumor suppressor function in the earliest stages of breast, colorectal, cutaneous and pancreatic carcinogenesis (Pierce et al., 1995; Sun et al., 1994; Wang et al., 1995a; Eppert et al., 1996; Markowitz et al., 1995; Takagi et al., 1996; Glick et al., 1993 Glick et al., , 1994 Cui et al., 1994; Hahn et al., 1996) .
The TGF-b ligands bind to and signal through a heteromeric complex of type I and type II receptors that are serine/threonine kinases (Massague and WeisGarcia, 1996) . The receptors for the TGF-b family have been cloned and it has been shown that the TGF-b type II receptor (TbRII) is necessary for ligand binding and growth suppression by TGF-b1 (Derynck, 1994; Massague and Polyak, 1995) . In addition, the recent cloning of DPC4 gene (Hahn et al., 1996) , and the recognition that the DPC4 protein product functions in the TGF-b signal transduction pathway has led to improved understanding of TGF-b signaling. Seven members of the vertebrate TGF-b family intracellular signaling pathways have been identi®ed, and by consensus are now referred to as Smad1 through Smad7 (Derynck et al., 1996) . DPC4 is now referred to as Smad4. Following binding of TGF-b to type II receptors, the ligand-bound type II receptor forms an oligomeric complex with the type I receptor, resulting in type I receptor phosphorylation. In the presence of this fully activated receptor complex, three concomitant events have been observed: (1) a signi®cant increase in the phosphorylation of Smad2; (2) the formation of Smad4/Smad2 hetero-oligomers and (3) translocation of these hetero-oligomers to the nucleus (Chen et al., 1996; Lagna et al., 1996) . Activation of this pathway has been linked to growth inhibition by TGF-b.
The TGF-b family of peptides (TGF-b) appears to have a major role as a growth inhibitor for the intestinal epithelium. TGF-b is a potent inhibitor of intestinal crypt cell proliferation (Kurokowa et al., 1987; Barnard et al., 1989) . This inhibition of cultured intestinal cell proliferation after TGF-b treatment is the result of mid-to-late G1 cell cycle arrest associated with downregulation of cyclin D1 (Ko et al., 1995) and inhibition of Cdk4-associated Rb kinase activity (Ko et al., 1998) . There is increased expression of TGF-b1 along with the TbRII in rat intestinal epithelial cells as they migrate from the proliferative compartment toward the lumenal and this pattern of expression is inversely correlated with the mitotic activity in the gut surface (Barnard et al., 1989 (Barnard et al., , 1993 Winesett et al., 1996; Zhang et al., 1997b) . These ®ndings suggest that TGF-b is a major autocrine or paracrine regulator of intestinal cell proliferation, and perhaps dierentiation.
TGF-b regulation of epithelial cell proliferation is altered by transformation. TGF-b inhibits growth of nontumorigenic human colonic adenoma cells in culture (Manning et al., 1991) . However, conversion of adenoma to a tumorigenic adenocarcinoma is associated with a decreased response to the inhibitory actions of TGF-b (Manning et al., 1991) . Studies in human colon carcinoma cell lines have demonstrated a correlation between the degree of dierentiation of the tumor and sensitivity to the antiproliferative and dierentiation-promoting eects of TGF-b (Hoosein et al., 1989) . Loss of responsiveness to the growthinhibitory eects of TGF-b occurs in many cancer cell types, including pancreatic , breast (Sun et al., 1994) and colorectal carcinoma cells (Hoosein et al., 1989) . Thus, loss of growth-inhibitory responses to TGF-b appears to be a common and important event that attends malignant transformation of epithelial cells.
One of the mechanisms by which tumor cells become resistant to the growth inhibitory actions of TGF-b may be through downregulation or mutation of the TbRII. Loss of TGF-b receptor function may lead the cells to escape from negative growth regulation by TGF-b. Several studies have suggested that loss of TbRII is a key step for the neoplastic transformation of epithelial cells (Arteaga et al., 1988 (Arteaga et al., , 1993 Kimchi et al., 1988; Sun et al., 1994) . Inactivation of the TbRII has been detected in a subgroup of colorectal carcinomas associated with the microsatellite instability or RER (replication error) phenotype which is found in approximately 13% of all colorectal cancers (Markowitz et al., 1995) . Restoration of the TbRII by stable transfection suppresses tumorigenicity of receptor negative colon cancer cells (Wang et al., 1995a) . Interestingly, mutations of the TbRII appear to be rare in the majority of colorectal carcinomas that do not have the RER phenotype. Mutational loss of function of critical TGF-b signal transduction proteins involved in growth-inhibitory responses, such as Madr2 (Smad2) (Eppert et al., 1996) and DPC4 (Smad4) (Takagi et al., 1996) , have also been documented in a small, but signi®cant, percentage of human colorectal carcinomas (estimated at 4 and 16%, respectively). In the absence of receptor or signaling mutation in the TGF-b pathway, downregulation of TbRII expression may also contribute loss of growth-inhibitory responses. A likely consequence of the decrease in the TGF-b type II receptor would be loss of sensitivity to growth inhibitory eect of TGF-b. Activating mutations of the K-ras gene occur with high frequency during the progression from adenoma to carcinoma in the colon and probably contribute to tumor progression (Kinzler and Vogelstein, 1996) . Transformation of rat intestinal epithelial cells (IEC-18 and RIE-1) by activated H-Ras results in downregulation of the TbRII accompanied by resistance to TGF-b growth inhibitory eects (Filmus et al., 1992; Winesett et al., 1996; Zhao and Buick, 1995) and increased levels of cyclin D1 expression (Filmus et al., 1994) . We have also observed greatly decreased expression of the TbRII that was inversely correlated with increased expression cyclin D1 and its catalytic partner Cdk4 in intestinal adenomas from Min/+ mice (Zhang et al., 1997a) . Does TGF-b have a role in promoting neoplasia? Contrasting with its roles as a growth-inhibitor and potential tumor suppressor, there is increasing evidence that TGF-b may play diverse roles in epithelial cell transformation. TGF-b may even promote tumorigenesis and may contribute to the metastatic phenotype of tumor cells. TGF-b expression tends to be increased in a wide variety of cancers (including colon cancer) relative to adjacent normal tissues (Derynck et al., 1987) . Transformation of cells with dominant oncogenes (eg Ha-ras or v-src) results in transcriptional activation of the TGF-b1 gene (Birchenall-Roberts et al., 1990; Geiser et al., 1994) . These observations suggest that tumor cells have lost the ability to respond to the growth-inhibitory eects of the relatively abundant TGF-b that is expressed in tumors. There are several lines of evidence that TGF-b may actually promote malignant transformation and tumor progression for several dierent cell types under selected circumstances. For example, TGF-b may suppress tumor immunosurveillance (Torre-Amione et al., 1990) . TGF-b exhibits growth-inhibitory eects on moderate to well-dierentiated primary colon carcinomas, but stimulates the proliferation and invasion of poorly-dierentiated and metastatic colonic carcinomas (Hafez et al., 1992; Schroy et al., 1990) . TGF-b1 can induce estrogen-independent tumorigenicity of human breast cancer cells (Arteaga et al., 1993) . TGF-b treatment can also substitute for wounding as a promoter of ®brosarcomas in chickens infected with the Rous sarcoma virus (Sieweke et al., 1990; Sieweke and Bissell, 1994) . Chronic exposure to high concentrations of TGF-b1 promotes the spontaneous neoplastic transformation of cultured rat liver epithelial cells . Cui et al. (1996) reported that TGF-b1 overexpression in transgenic mouse keratinocytes inhibited the appearance of carcinogeninduced benign skin tumors; but for more advanced lesions, TGF-b1 overexpression enhanced progression toward the malignant spindle-cell phenotype. In Rastransformed mammary epithelial cells TGF-b1 collaborates with oncogenic Ha-Ras to induce the malignant ®broblastoid phenotype with the ability to invade stroma (Oft et al., 1996) . These observations suggest that tumor cells have not only lost the growthinhibitory response to TGF-b, but also imply that TGF-b may promote the malignant transformation.
In the present study, we found that continuous exposure of non-tumorigenic intestinal epithelial (RIE-1) cells to TGF-b1 resulted in loss of TGF-b growth inhibitory responsiveness. Further, prolonged TGF-b1 treatment resulted in morphological transformation of the RIE cells and the acquisition of a tumorigenic phenotype that was associated with upregulation of cyclooxygenase-2 and downregulation of the TbRII.
Results

Selection of TGF-b resistant RIE cells (RIE-Tr)
The rat intestinal epithelial cells used for this study were the non-transformed RIE-1 cell line at passage #12. We noted that the growth-inhibitory eects of TGF-b on RIE-1 cells were transient. As shown in Figure 1a , addition of TGF-b signi®cantly inhibited cell growth. During the ®rst 6 days of TGF-b (120 pM) treatment, RIE-1 cell number was less than 25% of the (Figure 1b ).
Neoplastic transformation of RIE-Tr cells
RIE-1 cells were derived from normal undierentiated intestinal crypt cells, display properties of normal epithelial cells, and do not spontaneously undergo neoplastic transformation in the culture Brown, 1984, 1985) . To con®rm this we have selected more than 50 RIE-1 subclones. All subclones morphologically displayed a non-transformed phenotype. All tested subclones exhibited sensitivity to TGFb1 growth-inhibition (data not shown). We have not observed the parental RIE-1 cells to spontaneously undergo neoplastic transformation, even after continuous culture and multiple passages in parallel with the cultures continuously exposed to TGF-b1. The parental RIE-1 cells grow as a monolayer and are cuboidal and epithelioid in appearance in culture. When the parental cells reach con¯uence they undergo growth arrest from contact inhibition. In contrast, the RIE-Tr cells acquired a spindly, ®broblastoid morphology and appeared transformed. The growth characteristics of RIE-Tr cells were compared with those of the parental RIE-1 cells (Figure 2a ). Equal numbers of RIE-1 cells or RIE-Tr cells were seeded into 24-well plates. The RIE-1 cells reached con¯uence by about 8 days, and the cell number plateaued from day 8 to day 14. In contrast, the RIE-Tr cells grown under identical conditions reached con¯uence at day 6 after plating, but continued to increase in number for the entire 14-day period of this experiment. The number of RIE-Tr cells at day 14 was 3.4-fold greater than the number of RIE-1 cells. Unlike the RIE-1 cells, the RIE-Tr cells were not contact-inhibited and appeared to pile up into several layers and formed multiple foci in culture ( Figure 2b ). These ®ndings were further con®rmed by comparing DNA synthesis between con¯uent RIE-1 and RIE-Tr cells.
[ 3 H]thymidine incorporation assay revealed that the DNA synthesis rate in con¯uent RIETr cells was 2.2 ± 3-fold higher than the rate in con¯uent RIE-1 cells (Figure 2c ).
In addition to uncontrolled proliferation, resistance to apoptosis is another common feature of neoplastic transformed cells. We have previously shown that non-transformed RIE-1 cells were unable to grow in Matrigel (basement membrane) and underwent apoptosis by 4 days after plating in the Matrigel. In contrast, Ras-transformed RIE cells readily formed colonies in Matrigel (Sheng et al., 1997a) . RIE-Tr cells exhibited the ability to grow in Matrigel and to rapidly form colonies in Matrigel ( Figure 3a ). Sodium butyrate induces apoptosis in cultured intestinal epithelial cells (Hague et al., 1993; Tsujii and DuBois, 1995) . We compared the eect of sodium butyrate treatment on parental RIE-1 and RIE-Tr cells. Sodium butyrate (5 mM) was added to con¯uent RIE-1 and RIE-Tr cell cultures 24 h before the cells were harvested and assessed for DNA fragmentation as a measure of apoptosis. As demonstreated in Figure 3b , parental RIE-1 cells underwent low level, but detectable, apoptosis within 2 days of reaching con¯uence, and after 24 h of treatment with sodium butyrate there was a clear increase in oligonucleosomal DNA fragmentation as determined by neutral agarose gel electrophoresis. Neither con¯uence nor sodium butyrate treatment resulted in appreciable apoptosis in the RIE-Tr cells. Resistance to apoptosis could positively contribute to the uncontrolled growth of RIE-Tr cells. To determine whether the transformed appearance also indicated the invasiveness in the RIE-Tr cells, Boyden chamber invasion assays were performed. RIE-1 or RIE-Tr cells were plated onto the collagen-coated inserts. Media with varying concentrations of TGF-b1 were added to the lower chambers as treatment and chemoattractants. As demonstrated in Figure 3c , parental RIE-1 cells did not penetrate the membrane toward TGF-b1. Interestingly, RIE-Tr cells showed the ability to migrate into the lower chamber only when the media in the lower chamber contained TGF-b1 at concentrations of 5 and 10 ng/ml. An average of 23.4 cells per microscope ®eld (6200) penetrated the membrane toward 5 ng/ml of TGF-b1 indicating the invasive potential of RIE-Tr cells. This also con®rms that RIE-Tr cells remain responsive to exogenous TGF-b1.
To further compare the growth characteristics of RIE-Tr cells and the RIE-1 cells, their capacity for colony formation in soft agar was determined.
Varying numbers of RIE-1 and RIE-Tr cells (5610 2 to 1610 5 ) were seeded into soft agarose. No colonies were observed wtih parental RIE-1 cells. In contrast, the RIE-Tr cells from 5000 cells per plate to 75 000 cells per plate reproducibly formed colonies in soft agarose. The optimal cell concentration for colony formation was 10 000 cells per plate with an average of 115 colonies per plate. These results demonstrate that the RIE-Tr cells have acquired the capacity for anchorage-independent growth in soft agarose and further suggested that these cells had undergone neoplastic transformation in response to TGF-b1 treatment.
Since several phenotypic alterations suggestive of transformation had been observed in RIE-Tr cells, their potential for tumorigenicity was tested in nude mice. Either RIE-1 or RIE-Tr cells were injected into dorsal subcutaneous tissue of nude mice. There were visible tumors in eight of eight nude mice injectd with RIE-Tr cells within 7 days following the injection. There was no tumor growth in any of the mice that were injected with the parental RIE-1 cells during 2 months of observation. Routine hematoxylin and eosin stained sections showed a poorly dierentiated malignant neoplasm with focal intracytoplasmic mucin vacuoles, most consistent with a poorly dierentiated adenocarcinoma. Electron microscopic evaluation of sections taken from the solid tumors revealed the typical ultrastructural features of an adenocarcinoma, including tight junctions (Figure 3d ; inset 1), and the presence of primitive lumen formation (Figure 3d ; #2) with microvilli (Figure 3d ; #3). The growth of RIE-Tr tumors in nude mice was limited. The tumors grew up to 1 cm in diameter and then the growth stopped and the tumors remained unchanged for at least 3 months. The cells cultured from these quiescent tumors appeared morphologically to be nontransformed, similar to parental RIE-1 cells (data not shown). 4 cells were mixed in 0.5 ml of 1 : 2 diluted Matrigel (with DMEM medium) and plated in 24-well plates. The pictures were taken by using an inverted microscope 10 days after the cells were plated. (b) Comparison of sodium butyrate induced apoptosis in RIE-1 and RIE-Tr cells. For the DNA fragmentation assay, con¯uent cell cultures were established in 60 mm tissue culture plates. Either vehicle or 5 mM of sodium butyrate was added to the cultures for 24 h before the cells were harvested. The DNAs were separated on 1.6% agarose gel. (c) Boyden chamber invasion assay. 5610 4 cells in medium without supplementation of serum were added to the collagen type IV coated culture insert. Control medium or medium supplemented with varying concentrations of TGF-b1 (1, 2.5, 5, 10 ng/ml) was added to the lower chamber. The cells were incubated for 9 h and then ®xed with 2.5% glutaraldehyde and dyed with 0.5% crystal violet. Coating was removed and the cells that penetrated the membrane were counted at 2006 magni®cation. Columns, mean (n=9); Bars, s.e. (d) Electron micrograph of an adenocarcinoma formed by RIE-Tr cells in nude mice. The inset denoted by #1 demonstrates the formation of tight junctions at the arrow. Arrows at #2 depict primitive lumen formation and at #3 depict microvilli
in RIE-Tr cells
The expression of TGF-b1 was barely detectable in the parental RIE-1 cells at both the mRNA and protein levels. Compared with RIE-1 cells, a ®vefold increase in TGF-b1 mRNA (Figure 4a ) was observed in RIE-Tr cells. The elevation of TGF-b1 expression caused by TGF-b1 treatment suggests the autocrine regulation of TGF-b1 in RIE-Tr cells. In contrast, we were unable to detect expression of TGF-b2 and TGF-b3 mRNAs in the RIE-Tr cells (data not shown).
Escape from the negative growth regulatory eect of TGF-b due to loss of type II TGF-b receptor (TbRII) expression is suspected to be a factor for the neoplastic transformation in intestinal epithelial cells (Markowitz et al., 1995; Wang et al., 1995b) . As demonstrated in Figure 4a , the expression of TbRII mRNA in RIE-Tr cells was decreased by 25% as compared with the parental cells. In contrast, immunoblot analysis demonstrated a 95% decrease in TbRII protein levels in RIE-Tr cells as compared with the parental RIE cells, while the expression of TGF-b type I receptor was not changed (Figure 4b ). The rate of TbRII protein synthesis was decreased by 63% in the RIE-Tr cells as compared with the rate in RIE-1 cells, as determined by metabolic labeling experiment ( Figure  4c ). We previously reported that TGF-b1 treatment downregulates the expression of cyclin D1, and induces the expression of COX-2 in RIE cells (Ko et al., 1995 (Ko et al., , 1998 Sheng et al., 1997b) . To determine whether the targeted genes are still regulated by TGF-b1 treatment in RIE-Tr cells the regulation of cyclin D1 and COX-2 proteins was analysed. RIE-Tr cells were grown in the medium without supplementation of TGF-b1 for 24 h and then treated with a higher concentration (10 ng/ ml) of TGF-b1. Withdrawal of TGF-b1 for 24 h did not alter the levels of TbRII protein in RIE-Tr cells (data not shown). As shown in Figure 4d , the expression of cyclin D1 was signi®cantly inhibited and there was a further increase in the levels of COX-2 when RIE-Tr cells were treated with TGF-b1 for 8 and 24 h. This demonstrates that there is preserved TGF-b responsiveness in the RIE-Tr cells despite reduced expression of TbRII.
Overexpression of COX-2 may provide a selective survival advantage for intestinal epithelial cells (Tsujii and DuBois, 1995) . Therefore, we asked whether COX-2 expression was increased in the RIE-Tr cells. Steady state levels of COX-2 mRNA were 12.6-fold higher in the RIE-Tr cells than in the RIE-1 cells (Figure 4a ). COX-2 protein was expressed at very low levels (below the limits of detection) in mid-log phase RIE-P cells, whereas COX-2 protein was 40-fold more abundant in RIE-Tr cells (Figure 4b ). RIE-1 cells have been previously shown to produce prostacyclin as the predominant prostanoid which is quanti®ed by measuring its stable hydrolysis product, 6-keto-PGF 1a . Prostacyclin production, after treatment with 15 mM of arachidonic acid, was found to be 5.9-fold greater in the RIE-Tr cells as compared to parental RIE-1 cells (Figure 4e) .
In order to determine the kinetic regulation of COX-2 and TbRII by chronic TGF-b1 treatment, RIE-1 cells were treated with vehicle or 3 ng/ml TGF-b1 for various time intervals and cell lysates were collected.
The levels of COX-2 and TbRII proteins were analysed by Western blotting. As shown in Figure 4f , the persistent elevation of COX-2 and reduction of TbRII were observed after the RIE cells had been exposed to TGF-b1 (3 ng/ml) for 30 ± 40 days.
Growth inhibition by inhibitors of prostaglandin synthesis
In order to determine whether overexpression of COX-2 plays a role in the growth of RIE-Tr cells, the eect of cyclooxygenase inhibitors was examined. In preliminary experiments, the non-selective cyclooxygenase inhibitor sulindac sul®de and inhibited the proliferatioan of RIE-Tr cells in culture (data not shown). We next used a selective cyclooxygenase-2 inhibitor, SC-58125, (Seibert et al., 1994; Anderson et al., 1996; Masferrer et al., 1996) to treat the cultured cells. SC-58125 had no signi®cant eect on growth of the RIE-1 parental cells (Figure 5a ), but inhibited RIE-Tr cell growth in a concentrationa-dependent manner. Addition of 10, 25 and 50 mM of SC-58125 caused a decrease in RIE-Tr cell number by 37, 53 and 88% (Figure 5b ). Intraperitoneal administration of SC-58125 (10 mg/kg) suppressed tumor volumes of xenografted RIE-Tr cells in nude mice by 90% by day 42 (Figure 5c ).
Subcloning of RIE-Tr cells
In order to con®rm that the transformation of RIE-1 cells to neoplastic RIE-Tr cells by chronic exposure to TGF-b1 was reproducible, we generated RIE-Tr cells from three independent experiments. All three RIE-Tr cell pools demonstrated the malignant transformed phenotype. Forty subclones were selected from the three dierent experiments by the limiting dilution technique. Ninety per cent of these subclones expressed low levels of TbRII and high levels of COX-2 protein as had been observed in the original RIE-Tr cell pools. Expression of COX-2 and TbRII in ten subclones from three dierent RIE-Tr pools is demonstrated in Figure  6 . There was an inverse relationship between TbRII and COX-2 expression. The subclones that maintained a relatively greater abundance of TbRII expressed lower levels of COX-2. Subcutaneous xenografts from eight of the ten selected subclones developed tumors in nude mice within 2 months after inoculation of the cells. Clone #7 of RIE-Tr 2 and clone #4 of RIE-Tr3, which exhibited higher level expression of TbRII and lower expression of COX-2 did not form tumors in nude mice. These results indicate that prolonged TGF-b1 treatment reproducibly causes malignant transformation in the RIE-1 cells, and suggest that transformation of these cells is consistently associated with loss of TbRII and constitutive overexpression of cyclooxygenase-2.
Withdrawal of TGF-b1 from RIE-Tr cells
In order to determine whether the altered phenotype of RIE-Tr cells depends upon the presence of TGF-b1 we removed TGF-b1 from the culture media for RIE-Tr cells. As shown in Figure 7 , the up-regulation of COX-2 expression and down-regulation of TbRII required the continuous presence of TGF-b1. The level of COX-2 protein was signi®cantly reduced and the level of TbRII was increased upon withdrawl of TGF-b1 for 10
Transformation of intestinal epithelial cell and TGF-b1 H Sheng et al regulation of the expression of cyclin D1 and COX-2. RIE-Tr cells were incubated in the medium without supplementation of TGFb1 for 24 h and then treated with TGF-b1 at a concentration of 10 ng/ml. Protein lysates were collected at the indicated time points for determining the levels of cyclin D1 and COX-2 proteins. (e) Quantitation of eicosanoids in RIE-1 and RIE-Tr cell conditioned medium. Serum-free medium with 15 mM of arachidonic acid was replaced 1 h prior to collecting the conditioned medium. The prostacyclin formation in medium was quanti®ed by measuring 6-keto-PGF 1a utilizing stable isotope dilution techniques employing gas chromatography negative ion chemical ionization mass spectrometry. Columns, mean (n=3) and Bars, s.e. (f) Kinetic regulation of TbRII and COX-2 proteins by chronic TGF-b1 treatment. RIE-1 cells were seeded in 100 mm plates with addition of 3 ng/ml TGF-b1 or vehicle. The cells were split when they reached con¯uence. Cellular proteins were collected at the days indicated and analysed by Western blotting for TbRII and COX-2 days. When the RIE-Tr cells were cultured in the medium without supplementation of TGF-b1 for 20 days, the levels of COX-2 protein and TbRII protein normalized to levels similar to these in parental RIE cells. Withdrawal of TGF-b1 from the RIE-Tr cells resulted in a 77% reduction in Matrigel colony formation (Figure 7b ). In addition to decrease in colony number, there was a signi®cant reduction in colony size in the RIE-Tr cells that were grown in medium without TGF-b1 for 20 days (Figure 7c ).
Discussion
There is increasing evidence that TGF-b may play diverse roles in epithelial cell transformation. TGF-b1 inhibits the formation of carcinogen-induced benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice with keratinocyte-targeted expression of TGF-b1 (Cui et al., 1996) . A characteristic of the transformation from a preinvasive epithelial neoplasm to the invasive pheno- Figure 6 Expression of TbRII and COX-2 in RIE-Tr subclones. Three RIE-Tr pools (RIE-Tr1, RIE-Tr2, and RIE-Tr3) were independently established. Subclones (in arabic numbers) were isolated by limiting dilution. Immunoblotting analyses were employed for determination of protein levels of type II TGF-b receptor and cyclooxygenase-2. The results in RIE-1 parental cells (P) were shown as controls (Zambruno et al., 1995; Caulin et al., 1995) and mammary epithelial cells (Miettinen et al., 1994) . There is mounting evidence that autocrine TGF-b expression by tumor cells plays a major role in the epithelial®broblastoid conversion in mammary cells (Oft et al., 1996) and in keratinocytes (Caulin et al., 1995; Cui et al., 1996) that accompanies malignant transformation. Oft et al. (1996) recently demonstrated that TGF-b1 accounted for the ®broblastoid conversion and invasive phenotype of Ras-transformed mammary epithelial cells, but relatively short-term exposure to TGF-b1 (8 days) caused growth arrest and did not alter the cellular phenotype of control nontransformed mammary epithelial cells. Our current ®ndings are consistent with those described above in that prolonged TGF-b1 treatment resulted in conversion of RIE-1 cells to a tumorigenic phenotype with a ®broblastoid appearance.
Several studies have suggested that loss of TGF-b type II receptor is a key step for the neoplastic transformation of epithelial cells (Arteaga et al., 1988 (Arteaga et al., , 1993 Kimchi et al., 1988; Sun et al., 1994; Markowitz et al., 1995) . This may lead the cells to escape from negative growth regulation by TGF-b. Restoration of the type II TGF-b receptor in replication error-positive colon carcinoma cells lacking this receptor has been shown to reduce clonogenicity and tumorigenicity apparently through autocrine activity of TGF-b (Wang et al., 1995b) . We have observed that neoplastic transformation of non-transformed intestinal epithelial cells was accompanied by a decrease in type II TGF-b receptor levels in response to prolonged TGF-b1 exposure. The mechanism by which chronic exposure to TGF-b1 resulted in downregulation of level of TbRII protein in the RIE-Tr cells is complex. A *25% reduction in the expression of TbRII mRNA accounts for a part of decrease in TbRII protein. There is also *63% decrease in TbRII synthesis suggesting that a decrease in the rate of translation accounts for much of the decrease in the steady-state level of the TbRII protein in RIE-Tr cells. The high concentration of 4 cells were mixed in 0.5 ml of 1 : 2 diluted Matrigel and plated in 24-well plates. The pictures were taken by using an inverted microscope (magni®cation 640) after the cells were plated for 10 days exogenous along with increased endogenous TGF-b1 may bind to TbRII, cause internalization, and may contribute to increased degradation of TbRII protein, however direct evidence for this is lacking and is currently under investigation. A likely consequence of the decrease in the type II TGF-b receptor would be loss of sensitivity to the growth inhibitory eect of TGF-b. Interestingly, we and others have previously found that TbRII expression is decreased in early intestinal adenomas associated with loss of Apc function in mice (Zhang et al., 1997b; Oshima et al., 1997) .
The eect of TGF-b1 on malignant intestinal epithelial cells that have reduced TbRII is complex. Previous studies have shown that it is possible for cells to be refractory to the growth-inhibitory eect of TGF-b while retaining other TGF-b induced responses. Expression of a dominant negative type II TGF-b receptor interferes with TGF-b signaling because of apparent competition with wild-type II receptor for interction with the type I receptor (Chen et al., 1993) . Chen et al. (1993) demonstrated in mink lung epithelial cells (Mv1Lu) that overexpression of the dominant negative type II receptor (lacking the cytoplasmic kinase domain) resulted in loss of growth inhibition in response to TGF-b treatment; however, induction of plasminogen activator inhibitor-1 (PAI-1) and fibronectin proteins and JunB mRNA remained intact. In contrast, Wieser et al. (1993) found that the growthinhibitory response is suppressed in mink lung epithelial cells that expressed a kinase-de®cient TGFb type II receptor and there was a dose-dependent decrease in transcriptional responses to TGF-b with increasing concentrations of dominant negative gene transfection. Thus, both growth-inhibitory signaling and non-growth related signaling in response to TGF-b may be linked to the quantity of functional type II receptor; however, these responses may have differential sensitivities to the quantity of available activated type II receptor, and selected transcriptional eects may be preserved in cells that are resistant to the growth-inhibitory actions of TGF-b. Our observations that TGF-b1 causes phenotypic alterations in RIE-Tr cells in which type II TGF-b receptor is expressed at very low levels is consistent with this potential mechanism. Despite a 95% reduction in the level of type II TGF-b receptor in the RIE-Tr cells, their invasiveness, COX-2 upregulation, TbRII downregulation, and colony formation in Matrigel continue to require the presence of exogenous TGF-b1. Further, retreatment of RIE-Tr cells with TGF-b1 24 h after TGF-b1 removal resulted in downregulatioan of cyclin D1 and superinduction of COX-2, despite the fact that TbRII levels had not begun to recover.
There is now considerable evidence, from several dierent systems, that COX-2 plays a key role in the development of colorectal cancer. COX-2 expression has been found in 85% of human colorectal cancers (Eberhart et al., 1994) . Several studies have reported a 40 ± 50% decrease in the relative risk of colorectal cancer in persons who are continuous users of aspirin or other nonsteroidal antiin¯ammatory drugs (NSAIDs) (reviewed in Williams and DuBois, 1996; Prescott and White, 1996) . Cyclooxygenase-2 levels are increased in carcinogen-induced rat colonic tumors as compared with normal colon mucosa . Similar to the Multiple Intestinal Neoplasia (Min) mice, Apc D716 knockout mice develop multiple intestinal adenomas due to truncating mutations in the Apc gene (Oshima et al., 1996) . When the Apc D716 knockout mice were bred with mice that were null for the COX-2 gene, there was a marked reduction in tumor multiplicity. A selective COX-2 inhibitor was more eective than the nonselective NSAID Sulindac in reducing polyp number in the Apc D716 knockout mice. Treatment of rat intestinal epithelial cells with TGFb causes transient induction of COX-2 and increased prostaglandin production (Gilbert et al., 1994a,b; Sheng et al., 1997b) . In the present report, we have shown a dramatic increase in both COX-2 mRNA and protein, along with increase in production of prostacyclin in RIE-Tr cells after prolonged TGF-b1 treatment. In addition, a selective cyclooxygenase-2 inhibitor SC-58125 (Seibert et al., 1994; Masferrer et al., 1996) signi®cantly suppressed RIE-Tr cell growth in culture and in vivo. We have previously reported that selective inhibition of COX-2 activity inhibits the growth of a human colon cancer cell line that constitutively expresses a high level of COX-2, whereas it does not alter the growth of colon cancer cells that do not express COX-2 (Sheng et al., 1997c (Sheng et al., , 1998 . What is the role of COX-2 in intestinal cell transformation? Tsujii and DuBois (1995) found that COX-2 overexpression may contribute to the tumorigenic potential of dysplastic intestinal epithelial cells by enhancing adhesion to extracellular matrix and by inhibition of apoptosis. Expression of COX-2 also increases invasiveness and metastatic potential in human colon cancer cells (Tsujii et al., 1997) . Our results provide further evidence that an increase in expression of COX-2 may be an early and biologically signi®cant event in the malignant transformation of intestinal epithelial cells. Based on the results of our experiments with the COX-2 inhibitors, the transformed phenotype of the RIE-Tr cells appears, at least in part, to be dependent on COX-2 activity.
In summary, colorectal carcinogenesis often involves an increase in the expression of TGF-bs. There is mounting evidence that while TGF-b is a potent inhibitor of epithelial cell growth, under selected conditions, it appears to have an important role in tumor promotion. There is also cumulative evidence that COX-2 plays an important role in early intestinal neoplasia and that TGF-b1 is a potent inducer of COX-2 expression. In the present study, we found that chronic TGF-b1 treatment caused constitutive expression of COX-2 coupled with downregulation of the TGF-b type II receptor, and these changes were associated with malignant transformation of intestinal epithelial cells. The activity of the overexpressed COX-2 appears to be important for the transformed phenotype, as treatment with the COX-2 antagonist inhibited the growth of the RIE-Tr cells and reduced the tumorigenicity.
Materials and methods
Cell culture and growth study
Rat intestinal epithelial (RIE-1) cells were a gift from KD Brown (Cambridge Research Station, Babraham, Cambridge, UK). The cells were maintained in Dulbecco's modi®ed Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Hyclone Laboratories Logan, UT, USA). Porcine platelet TGF-b1 (R&D systems, Inc. Minneapolis, MN, USA) and human recombinant TGF-b1 (a kind gift from Genentech) were used for cell treatment. Both types of TGF-b1 exhibit the same eect on RIE-1 cell growth. For the cell growth study, 2610 4 cells were seeded into multiple well plates. Media were replaced every 3 days, and cells were counted on the indicated days using a hemocytometer. Each number shown on the Figures represents the average cell number of triplicate wells.
RNA extraction and Northern blot analysis
Total cellular RNA was extracted according to Chirgwin et al. (1979) . RNA samples (20 mg per lane) were separated on formaldehyde-agarose gels and blotted onto nitrocellulose membranes. The blots were hybridized with cDNA probes labeled with a-32 P-dCTP by random primer extension. After hybridization and washes, the blots were exposed to X-ray ®lm for autoradiography. 188S rRNA signals were used as internal controls to determine the integrity of the RNA and the equality of loading among lanes.
Immunoblot analysis
Immunoblot analysis was done as previously described (Ko et al., 1995) . Brie¯y, the cells were lysed for 30 min in radioimmunoprecipitation assay (RIPA) buer (16PBS, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mg/ml phenylmethyl-sulfonyl¯uoride, 10 mg/ml aprotinin, 1 mM sodium orthovanadate), then the clari®ed cell lysates were denatured and fractionated by SDS ± PAGE. After electrophoresis, the proteins were transferred to nitrocellulose membrane. The ®lters were then probed with the indicated antibodies, developed by Enhanced Chemiluminescence System (Amersham, Arlington Heights, IL, USA), and exposed to XAR5 ®lm (Kodak, Rochester, NY, USA). Quantitation was determined by video densitometry. Anti-TGF-b1, type 1, and type II TGF-b receptor antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-cyclooxygenase-2 antibody was purchased from Oxford Biomedical Research (Oxford, MI, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Apoptosis
Con¯uent cell cultures were established in 60 mm plates. Either the control vehicle or 5 mM of sodium butyrate was added to the culture medium. The cells were incubated for another 24 h, then lysed in lysis buer (1% NP-40 in 20 mM EDTA and 50 mM Tris, pH 7.5). The supernatant containing fragmented DNA was clari®ed by centrifugation for 5 min at 1600 g. After the cell lysate was digested with proteinase K (2.5 mg/ml) and RNase A (5 mg/ml) the DNA was separated on 1.6% agarose gel.
Cell growth in Matrigel
5610
4 cells were suspended in 0.5 ml of 1 : 2 diluted Matrigel (Collaborative Biomedical Products, Bedford, MA, USA). The mixture was plated into 24-well plates. One ml complete medium was added to cover the Matrigel and was replaced every 3 days. Photographs of the colonies formed in Matrigel were taken on the 10th day by using an inverted microscope.
Boyden chamber invasion assay
5610
4 cells in medium without supplementation of serum were added to the collagen type IV coated culture insert.
Control medium or medium supplemented with varying concentrations of TGF-b1 (1, 2.5, 5 and 10 ng/ml) was added to the lower chamber. The cells were incubated for 9 h and then ®xed with 2.5% glutaraldehyde and dyed with 0.5% crystal violet. Coating was removed and the cells that penetrated the membrane were counted at 2006 magnification.
Anchorage-independent growth assay 5610 2 ± 10 5 cells were mixed with Sea plaque agarose (Hoeer Scienti®c Instrument, San Francisco, CA, USA) at a ®nal concentration of 0.4% in DMEM medium containing 10% FBS, and laid on top of a 0.8% agarose layer containing DMEM medium and 10% FBS in 35 mm plate. The plates were incubated for 2 ± 3 weeks. The colonies (450 mm) were counted on colony counter. All assays were performed with triplicate plates.
Tumorigenicity assay
10
6 cells suspended in 0.2 ml of DMEM medium were injected into the dorsal subcutaneous tissue of nude mice (Balb/c nu/nu., Harlan Sprague Dawley Inc, Indianapolis, IN, USA). The animals were monitored for tumor formation every week and sacri®ced 2 months later. Tumor tissues were ®xed for histological and electron microscopic examination. In order to examine the role of COX-2 on the establishment and growth of tumors in vivo, either vehicle (DMSO) or SC-58125 (10 mg/kg) was injected (i.p.) prior to the inoculation of cells. The treatments were continued three times per week until the animals were sacri®ced. Tumor volumes were measured and calculated according to the equation V=L6W 2 60.5, where V=volume, L=length and W=width (Wang et al., 1995b) .
Quantitation of eicosanoids
For this experiment, subcon¯uent cell cultures were established. Serum free medium supplemented with arachidonic acid (15 mM) (Cayman Chemical, Ann Arbor MI, USA) was replaced 1 h prior to collecting the conditioned medium. The prostacyclin formation in medium was quanti®ed by measuring 6-keto-PGF 1a utilizing stable isotope dilution techniques employing gas chromatography negative ion chemical ionization mass spectrometry. The results are expressed as ng of prostacyclin per 10 6 cells.
Metabolic labeling
Subcon¯uent cultures of RIE-1 and RIE-Tr cells were established. Two hours prior to harvesting, culture medium was replaced with methionine-free DMEM supplemented with 10% FBS and 300 mCi/ml of [ 35 S]methionine (Amersham, Arlington Heights, IL, USA). Cell lysates were prepared in RIPA buer. Equal amounts of protein from each sample was immunoprecipitated with anti-TbRII antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) conjugated protein-A sepharose (Sigma, St Louis, MO, USA), resolved by SDS ± PAGE, and visualized by autoradiography.
Abbreviations TGF-b, transforming growth factor b; TbRII, type II TGF-b receptor; COX-2, cyclooxygenase-2; RIE-1, rat intestinal epithelial cell; SC-58125, {1-[(4-methylsulfonyl)phenyl]-3-tri¯uoromethyl-5-[(4-¯uoro)phenyl]pyrazole}.
